Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Oksygenterapi hos barn og ungdom med Downs syndrom og obstruktiv søvnapné (DOSA)

25. september 2026 oppdatert av: Susan Redline, Brigham and Women's Hospital

Randomisert kontrollforsøk av oksygenterapi hos barn og ungdom med Downs syndrom og obstruktiv søvnapné

The purpose of this study is to assess whether oxygen supplementation during sleep improves working memory and other clinical and patient-reported outcomes among children who have Down Syndrome (DS) with moderate to severe Obstructive Sleep Apnea (OSA).

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

This will be a randomized, single-blind 6-month Phase-2 clinical trial that compares the impact of oxygen therapy during sleep on measures of cognition, behavior, quality of life, cardiac structure and function, and sleep in children with Down Syndrome(DS) with moderate to severe obstructive sleep apnea.

The proposed study will involve participation of children and their caregivers. Children will be recruited from each site's sleep clinics and laboratories, Down syndrome clinics and otolaryngology clinics. Community recruitment will be coordinated with local Down Syndrome Associations.

Children who agree to participate in the study will be screened for eligibility based on history, physical examination, and review of medical records including history of congenital heart disease and Pulmonary Hypertension (PHTN), and use of Continuous Positive Airway Pressure (CPAP). Children eligible for the study are those with persistent obstructive apnea after adenotonsillectomy or children with obstructive sleep apnea without adenotonsillar hypertrophy or in situations when parents refuse adenotonsillectomy.. The enrollment PSG eligibility will be determined by central scoring of either a research Polysomnography (PSG). In addition to an oxygen titration PSG, which determines responsiveness to oxygen, participants will be asked to wear a wrist actigraph and undergo neurocognitive testing, echocardiography, physical examination, anthropometry, and venipuncture. Caregivers will complete questionnaires to assess their child's emotional, physical, social, and school functioning, sleep quality; child's behavior and cognitive function, and will complete a sleep diary that is used concurrently with their child's use of a wrist actigraph. The latter includes caregiver completion of the "Behavior Rating Inventory of Executive Function" (BRIEF2), a co-primary outcome.

At 3 months, caregivers will complete the BRIEF2. At 6 months, all baseline studies and a PSG will be repeated.

At baseline, demographic data will be collected, including information on residential address (for use in geocoding).

Studietype

Intervensjonell

Registrering (Antatt)

230

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • California
      • Los Angeles, California, Forente stater, 90027
        • Rekruttering
        • Children's Hospital of Los Angeles
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sally Ward, MD
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • Rekruttering
        • University of Michigan, Ann Arbor Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ronald Chervin, MD
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45229
        • Rekruttering
        • Cincinnati Children's Hospital Medical Center
        • Hovedetterforsker:
          • Raouf Amin, MD
        • Ta kontakt med:
      • Cleveland, Ohio, Forente stater, 44106
        • Rekruttering
        • Rainbow Babies and Children's Hospital, Case Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sally Ibrahim, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia
        • Ta kontakt med:
        • Hovedetterforsker:
          • Christopher Cielo, MD
    • Virginia
      • Norfolk, Virginia, Forente stater, 23507
        • Rekruttering
        • East Virginia Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Cristina Baldassari, MD
    • Washington
      • Seattle, Washington, Forente stater, 98105

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

5 år til 18 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Ages 5.0 to 17.9 years at the time of screening

  2. Children with OSA and obstructive apnea hypopnea index (OAHI) ≥5/hour.

  3. Absence of clinically significant hypoxia defined as oxygen saturation <88% for 5 minutes or episodic desaturation to 60% as these levels would otherwise identify children eligible to routinely receive oxygen.

  4. Favorable response to oxygen therapy (allowing randomization) will be defined as follows:

    1. Oxygen saturation nadir >92% and
    2. Decrease in obstructive index < 5 / hour or by > 50% from screening PSG
    3. Reaching an optimum oxygen flow which is defined as the flow that achieves the lowest level of AHI with maximum CO2 level less than 65 mmHg observed for 5 consecutive minutes and or an increase in CO2 by less than 15 points above baseline. The above criteria are observed while the patient spends a minimal of 30 minutes in the supine position and at least one cycle of rapid eye movement (REM) sleep.
    4. Oxygen flow required does not exceed 3.0 LPM and does not exceed a FiO2 > 40 %.
  5. Willingness to comply with all study procedures and available for duration of study.

  6. At baseline the participant attempts to perform the neuropsychological tests

Exclusion Criteria:

  1. Current CPAP use with documented compliance(> 4 hrs/ night; > 70% of nights).
  2. Oxygen saturation < 90% at rest during wakefulness.
  3. Chronic daytime or nighttime use of supplemental oxygen.
  4. Smoker in the child's bedroom.
  5. Unrepaired congenital heart disease.
  6. Moderate to severe pulmonary hypertension requiring treatment with oxygen and or pulmonary vasodilator.
  7. Unable to participate in a PSG.
  8. Individuals who develop alveolar hypoventilation with oxygen as previously defined.
  9. Other severe chronic diseases determined by their provider as making them poor study candidates.
  10. Enrolled or planning to enroll in another study that may conflict with protocol requirements or confound results in this trial.
  11. Documented clinically significant untreated hypothyroidism
  12. Children with adenotonsillar hypertrophy who are candidates for adenotonsillectomy and parents agree to the surgery.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Oxygen plus supportive care (OXT)

Nocturnal oxygen therapy plus providing patient with healthy sleep habits materials, healthy diet materials and nasal dilators.

Active nocturnal oxygen concentrator

Ingen inngripen: Supportive care (SC)

Providing patient with healthy sleep habits materials, healthy diet materials and nasal dilators.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Behavior Rating Inventory of Executive Function 2 (BRIEF2) working memory score
Tidsramme: Baseline and 6 months

Change from baseline in the Behavior Rating Inventory of Executive Function 2 (BRIEF2) working memory score (BRIEF2wm). The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 months
Differential Ability Scales - 2nd Edition (DAS-II) T-score.
Tidsramme: Baseline and 6 months

Change from baseline in the Differential Ability Scales - 2nd Edition (DAS-II) recognition of pictures (DAS2RoP) T-score. The score ranges from 10-90. A higher score is a better outcome.

Baseline and 6 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Total raw score
Tidsramme: Baseline and 6 Months

Change from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Total raw score. The score ranges from 0-64. A higher score is a better outcome.

Baseline and 6 Months
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Verbal raw score
Tidsramme: Baseline and 6 Months

Change from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Verbal raw score. The score ranges from 0-30. A higher score is a better outcome.

Baseline and 6 Months
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Non Verbal raw score
Tidsramme: Baseline and 6 Months

Change from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Non Verbal raw score. The score ranges from 0-34. A higher score is a better outcome.

Baseline and 6 Months
Differential Ability Scales-2 (DAS-II) Recall of Digits Forward raw score
Tidsramme: Baseline and 6 Months

Change from baseline in Differential Ability Scales-2 (DAS-II) Recall of Digits Forward raw score. The score ranges from 0-38. A higher score is a better outcome.

Baseline and 6 Months
Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) adjusted total errors based on stages completed
Tidsramme: Baseline and 6 Months

Change from baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) adjusted total errors based on stages completed

Baseline and 6 Months
Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI)
Tidsramme: Baseline and 6 Months

Change from baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI)

Baseline and 6 Months
Developmental Neuropsychological Assessment 2nd Edition (NEPSY-II) verbal fluency test raw score
Tidsramme: Baseline and 6 Months

Change from baseline in Developmental Neuropsychological Assessment 2nd Edition (NEPSY-II) verbal fluency test raw score. Range-N/A

Baseline and 6 Months
Observer Memory Questionnaire - Parent Form (OMQ-PF) total T-score
Tidsramme: Baseline and 6 Months

Change from baseline in Observer Memory Questionnaire - Parent Form (OMQ-PF) total T-score. The score ranges from 0-135. A higher score is a better outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for subscales (Inhibit, Self-Monitor, Shift, Emotional Control, Initiate)
Tidsramme: Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for subscales (Inhibit, Self-Monitor, Shift, Emotional Control, Initiate).

Baseline and 6 Months
Child Behavior Checklist (CBCL) T-scores for domains (Internalizing, Externalizing, Total Problems).
Tidsramme: Baseline and 6 Months

Change from baseline in Child Behavior Checklist (CBCL) T-scores for domains (Internalizing, Externalizing, Total Problems).

Baseline and 6 Months
Child Behavior Checklist (CBCL) T-scores for subscales (Attention Problems, Thought Problems, Rule-Breaking Behaviors, Aggressive Behaviors)
Tidsramme: Baseline and 6 Months

Change from baseline in Child Behavior Checklist (CBCL) T-scores for subscales (Attention Problems, Thought Problems, Rule-Breaking Behaviors, Aggressive Behaviors)

Baseline and 6 Months
KIDSCREEN-27 T-score
Tidsramme: Baseline and 6 Months

Change from baseline in KIDSCREEN-27 T-score, including domains of: physical well-being; psychological well-being; autonomy and parent relations; social support and peers; school environment. Range-N/A

Baseline and 6 Months
Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance T-score
Tidsramme: Baseline and 6 Months

Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance T-score. The score ranges from 28.7-85.6. A higher score is a worse outcome.

Baseline and 6 Months
Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score
Tidsramme: Baseline and 6 Months

Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score. The score ranges from 37.9-86.6. A higher score is a worse outcome.

Baseline and 6 Months
Presence of right ventricular hypertension
Tidsramme: Baseline and 6 Months

Presence of right ventricular hypertension as measured by tricuspid regurgitation continuous wave peak velocity (defined as a ratio of pulmonary artery pressure / systolic arterial pressure (PAP/SAP) >1/3); interventricular septal flattening as measured by eccentricity index (defined as systolic ratio of >1.25)

Baseline and 6 Months
Wechsler Intelligence Scale (WISC) for Children 5th edition (WISC-5) Cancellation raw score
Tidsramme: Baseline and 6 Months

Change from baseline of Wechsler Intelligence Scale (WISC) for Children 5th edition (WISC-5) Cancellation raw score. The score ranges from 0-128. A higher score is a better outcome.

Baseline and 6 Months
Wechsler Preschool and Primary Scale of Intelligence 4th edition (WPPSI-4) Cancellation task raw score
Tidsramme: Baseline and 6 Months

Change from baseline in Wechsler Preschool and Primary Scale of Intelligence 4th edition (WPPSI-4) Cancellation task raw score (if unable to complete Wechsler Intelligence Scale 5th edition Cancellation test). The score ranges from 0-96. A higher score is a better outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Behavior Regulation Index (BRI) domain.
Tidsramme: Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Behavior Regulation Index (BRI) domain. The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Emotional Recognition Index (ERI) domain.
Tidsramme: Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Emotional Recognition Index (ERI) domain. The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Cognitive Regulation Index (CRI) domain.
Tidsramme: Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Cognitive Regulation Index (CRI) domain. The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 Months
7-day actigraphy measurement of sleep efficiency
Tidsramme: Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of sleep efficiency

Baseline and 6 Months
7-day actigraphy measurement of time wake after sleep onset
Tidsramme: Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of time wake after sleep onset

Baseline and 6 Months
7-day actigraphy measurement of sleep fragmentation
Tidsramme: Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of sleep fragmentation

Baseline and 6 Months
7-day actigraphy measurement of total sleep duration
Tidsramme: Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of total sleep duration

Baseline and 6 Months
Polysomnography (PSG) AHI parameter
Tidsramme: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) AHI parameter. The score ranges from 0- >40. A higher score is a worse outcome.

Baseline and 6 Months
Polysomnography (PSG) percentage time of O2 <90 % parameter
Tidsramme: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) percentage time of O2 <90 % parameter

Baseline and 6 Months
Polysomnography (PSG) sleep apnea associated hypoxic burden parameter
Tidsramme: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) sleep apnea associated hypoxic burden, parameter

Baseline and 6 Months
Polysomnography (PSG) end-tidal CO2 level, parameter
Tidsramme: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) end-tidal CO2 parameter.

Baseline and 6 Months
Polysomnography (PSG) -based measure of sleep stages
Tidsramme: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of sleep stages. Range- N/A

Baseline and 6 Months
Polysomnography (PSG) -based measure of EEG power bands
Tidsramme: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of EEG power bands

Baseline and 6 Months
Polysomnography (PSG) -based measure of spindle morphology
Tidsramme: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of spindle morphology

Baseline and 6 Months
Polysomnography (PSG) -based measure of spindle numbers
Tidsramme: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of spindle numbers

Baseline and 6 Months
Polysomnography (PSG) -based measure of spindle density
Tidsramme: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of spindle density

Baseline and 6 Months
Polysomnography (PSG) -based measure of slow wave oscillations
Tidsramme: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of slow wave oscillations

Baseline and 6 Months
Left ventricular diastolic function as measured by Mitral E and A wave (E:A ratio)
Tidsramme: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Mitral E and A wave (E:A ratio)

Baseline and 6 Months
Left ventricular diastolic function as measured by E wave deceleration time
Tidsramme: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by E wave deceleration time

Baseline and 6 Months
Left ventricular diastolic function as measured by Mitral septal and lateral e' and a' (E/e')
Tidsramme: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Mitral septal and lateral e' and a' (E/e')

Baseline and 6 Months
Left ventricular diastolic function as measured by Mitral lateral tissue Doppler isovolumic relaxation time
Tidsramme: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Mitral lateral tissue Doppler isovolumic relaxation time

Baseline and 6 Months
Left ventricular diastolic function as measured by Pulmonary vein A wave reversal duration
Tidsramme: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Pulmonary vein A wave reversal duration

Baseline and 6 Months
Left ventricular diastolic function as measured by Left atrial volume
Tidsramme: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Left atrial volume

Baseline and 6 Months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

24. oktober 2023

Primær fullføring (Antatt)

30. november 2027

Studiet fullført (Antatt)

30. desember 2027

Datoer for studieregistrering

Først innsendt

17. august 2023

Først innsendt som oppfylte QC-kriteriene

12. september 2023

Først lagt ut (Faktiske)

21. september 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

25. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere